BXM Wealth’s VanEck Pharmaceutical ETF PPH Stock Holding History

BXM Wealth’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,120	Closed	-$324K	–	170
2026 Q1	$324K	Buy	+3,120	New	+$332K	0.25%	88

Other funds holding PPH

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Rye Brook Capital Greenwich, Connecticut $143M AUM 33.65% 1-Year Est. Return

WT Wealth Management Scottsdale, Arizona $361M AUM 23.03% 1-Year Est. Return

Fluent Financial Dallas, Texas $280M AUM 16.1% 1-Year Est. Return

AAFMAA Wealth Management & Trust Fayetteville, North Carolina $286M AUM 19.57% 1-Year Est. Return

Cassady Wealth & Retirement Planning Henderson, Nevada $215M AUM

Avior Wealth Management Omaha, Nebraska $3.8B AUM 23.28% 1-Year Est. Return

ARQ Wealth Advisors Scottsdale, Arizona $807M AUM 19.58% 1-Year Est. Return

Warner Financial Bethesda, Maryland $340M AUM 22.81% 1-Year Est. Return

Telos Capital Management San Diego, California $1.13B AUM 27.95% 1-Year Est. Return

BXM Wealth's PPH Position: Q2 2026 in Review

BXM Wealth sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2026, closing a stake of 3,120 shares — an estimated $324K sold.

BXM Wealth first reported a position in PPH in Q1 2026 and held it in 1 quarter. The position peaked at $324K in Q1 2026. 27 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

BXM Wealth reported no remaining VanEck Pharmaceutical ETF position as of Q2 2026 after selling out during the quarter.
BXM Wealth sold 3,120 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $324K.
BXM Wealth first reported a position in VanEck Pharmaceutical ETF in Q1 2026 and held it in 1 quarter.
BXM Wealth's VanEck Pharmaceutical ETF position peaked at $324K in Q1 2026.
27 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on BXM Wealth's 13F filing for Q2 2026, filed 27 Jul 2026.